Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma

Loretta J. Nastoupil, Nancy L. Bartlett

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases. Several recent advances have affected the treatment landscape, which had been mostly stagnant for the past few decades. We will review the practice-changing studies in frontline (POLARIX), early relapse (ZUMA-7 and TRANSFORM), and multiple recurrent (ZUMA-1, JULIET, TRANSCEND, L-MIND, and LOTIS-2) stages and discuss how the treatment landscape may evolve with the emergence of bispecific antibodies.

Original languageEnglish
Pages (from-to)903-913
Number of pages11
JournalJournal of Clinical Oncology
Issue number4
StatePublished - Feb 1 2023


Dive into the research topics of 'Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma'. Together they form a unique fingerprint.

Cite this